Toll-like Receptor Pipeline, Clinical Trials Studies, Emerging Drugs, Agreements & Collaborations, and Latest News 2023 (Updated)

DelveInsight's, "Toll- Like Receptor Agonist Pipeline Insight 2023" report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Toll- Like Receptor Agonist pipeline landscape. It covers the Toll-like Receptor pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Toll-like Receptor pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Toll-like Receptor Pipeline Report
• DelveInsight's Toll-like Receptor pipeline report depicts a robust space with 60+ active players working to develop 60+ pipeline therapies for Toll-like Receptor treatment.
• The leading companies working in the Toll-like Receptor Market include InDex Pharmaceuticals, Mologen, Idera Pharmaceuticals, Exicure, Birdie Biopharmaceuticals/ Seven and Eight Biopharmaceuticals, and others.
• Promising Toll-like Receptor Pipeline Therapies in the various stages of development include SD-101, Ribavirin, DSP-0509, GSK1795091, NI-0101, OPN-305, Durvalumab, Tremelimumab, and others.
• October 2023: EMD Serono Research & Development Inc. announced a study of Phase 2 clinical trials for M5049 High Dose. The purpose of this study is to evaluate the efficacy and safety of orally administered M5049 in idiopathic inflammatory myopathies, specifically dermatomyositis (DM) and polymyositis (PM) participants for 24 weeks. A Phase IIa, Randomized, Parallel, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Enpatoran in Dermatomyositis and Polymyositis Participants Receiving Standard of Care (NEPTUNIA).
• October 2023: Merck Healthcare announced a study of Phase 2 clinical trials for M5049 Low Dose. The purpose of the study is to evaluate the long term safety and efficacy of orally administered M5049 in participants with subacute cutaneous lupus erythematosus (SCLE), discoid lupus erythematosus (DLE) and/or systemic lupus erythematosus (SLE) who have completed the 24 week treatment period of Willow study (MS200569_0003 [NCT05162586]).A Phase II, Double-blind, Dose-Ranging, Parallel, Long-term Extension Study to Evaluate the Safety and Efficacy of Enpatoran in Participants With Subacute Cutaneous Lupus Erythematosus, Discoid Lupus Erythematosus and/or Systemic Lupus Erythematosus Having Completed the WILLOW (MS200569_0003) Study Treatment (WILLOW LTE).
• August 2023: University of California announced a study of Phase 1 clinical trials for Nivolumab and TLR9 Agonist SD-101. This phase I trial studies the side effects of SD-101 when given together with nivolumab and radiation therapy in treating patients with pancreatic cancer that does not respond to treatment with chemotherapy (chemotherapy refractory) and has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as SD-101, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving SD-101, nivolumab, and radiation therapy may work better in treating patients with pancreatic cancer compared to nivolumab or radiation therapy alone.
• July 2023: SURGE Therapeutics announced a study of phase 1 & 2 clinical trials for STM-416. This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients with bladder cancer. This is a 2-part, multicenter, first-in-human (FIH), Phase 1/2a study in patients with a history of pathologically confirmed high-grade Ta or T1 NMIBC without CIS who have completed SOC previously, with recurrent papillary disease seen on cystoscopy, and who are undergoing TURBT without perioperative intravesical chemotherapy. All patients will receive relevant SOC therapy following TURBT. SOC will be administered in the adjuvant setting.
• April 2023: Sumitomo Pharma America Inc. announced a study of Phase 1 & 2 clinical trials for Pembrolizumab and DSP-0509. This is a multi-center, Phase 1 / 2 clinical study for patients with advanced solid tumors. The study consists of 2 treatment arms - a monotherapy arm and a combination arm. The monotherapy arm has 1 part: Dose Escalation (Part A) The combination arm has Dose Escalation (Part B) only. The primary objective of Monotherapy Arm A is to determine the MTD or RP2D of DSP-0509 when administered as a single agent. Approximately 21 to 30 patients with advanced solid tumors will be enrolled. Several provisional dose levels of DSP-0509, with approximately 3 to 6 patients at each level may be tested in patients with advanced solid tumors. DSP-0509 will be administered as a single agent q2w beginning on Day 1.

Request a sample and discover the recent advances in Toll-like Receptor Treatment Drugs @ Toll-like Receptor Pipeline Report- https://www.delveinsight.com/report-store/toll-like-receptor-agonist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Toll-like Receptor pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Toll-like Receptor NDA approvals (if any), and product development activities comprising the technology, Toll- Like Receptor Agonist collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Toll-like Receptor Overview
Toll-like receptors (TLRs) are a family of pattern recognition receptors and part of the first line of defense against invading microbes. TLR1, -2, -4, -5, -6, and -10 are expressed on the cell surface, whereas TLR3, -7, -8, and -9 are situated on endosomal membranes within the cell [5, 9, 10]. TLR1 and TLR2 can heterodimerize to recognize a variety of bacterial lipid structures and cell wall components, such as triacylated lipoproteins, lipoteichoic acid, and β-glucans.

Find out more about Toll-like Receptor Therapeutics Assessment @ Toll-like Receptor Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/toll-like-receptor-agonist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Toll-like Receptor Emerging Drugs Profile
• Cobitolimod: InDex Pharmaceuticals
• Tilsotolimod: Idera Pharmaceuticals

Toll-like Receptor Pipeline Therapeutics Assessment
There are approx. 60+ key companies which are developing the Toll-Like Receptor Agonist therapies. The Toll- Like Receptor Agonist companies which have their Toll- Like Receptor Agonist drug candidates in the most advanced stage, i.e. Phase III include, InDex Pharmaceuticals.

DelveInsight's Toll-like Receptor Pipeline report covers around 60+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Toll- Like Receptor Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Learn more about the emerging Toll-like Receptor Pipeline Therapies @ Toll-like Receptor Clinical Trials Assessment- https://www.delveinsight.com/sample-request/toll-like-receptor-agonist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Toll-like Receptor Pipeline Report
• Coverage- Global
• Toll-like Receptor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Toll-like Receptor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Toll-like Receptor Companies- InDex Pharmaceuticals, Mologen, Idera Pharmaceuticals, Exicure, Birdie Biopharmaceuticals/ Seven and Eight Biopharmaceuticals, and others.
• Toll-like Receptor Pipeline Therapies- SD-101, Ribavirin, DSP-0509, GSK1795091, NI-0101, OPN-305, Durvalumab, Tremelimumab, and others.

Dive deep into rich insights for new drugs for Toll-like Receptor Treatment, Visit @ Toll-like Receptor Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/toll-like-receptor-agonist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Toll- Like Receptor Agonist: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Cobitolimod: InDex Pharmaceuticals
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. Cavrotolimod: Exicure
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I)
13. BDB-018: Seven and Eight Biopharmaceuticals
14. Drug profiles in the detailed report…..
15. Preclinical stage products
16. BDB-030: Seven and Eight Biopharmaceuticals
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Toll- Like Receptor Agonist Key Companies
20. Toll- Like Receptor Agonist Key Products
21. Toll- Like Receptor Agonist- Unmet Needs
22. Toll- Like Receptor Agonist- Market Drivers and Barriers
23. Toll- Like Receptor Agonist- Future Perspectives and Conclusion
24. Toll- Like Receptor Agonist Analyst Views
25. Toll- Like Receptor Agonist Key Companies
26. Appendix

For further information on the Toll-like Receptor Pipeline therapeutics, reach out to Toll-like Receptor Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/toll-like-receptor-agonist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Recently Published Most Important Links-
https://jobs.recruitingblogs.com/employers/2384764-delveinsight
http://samus.vforums.co.uk/profile/dennydonesdi
http://supportskin.vforums.co.uk/profile/dennydonesdi
http://wwa.vforums.co.uk/profile/dennydonesdi
http://music.vforums.co.uk/general/2838/delveinsight
http://nuchinuxri.vforums.co.uk/profile/dennydones91021
http://raf.vforums.co.uk/profile/dennydonesdi
http://france.vforums.co.uk/Suggestions/1797/market-research-reports
http://thecir.vforums.co.uk/profile/dennydonesdi
http://lol.vforums.co.uk/profile/dennydonesdi
https://www.openlearning.com/u/havensmith-s2ry19/
https://dennydones9.cgsociety.org/profile
https://www.f6s.com/member/denny-dones
https://www.minecraftforum.net/members/dennydones9?__cf_chl_tk=ljVLvJPBSq9.mVHsoWgwPjJb0A23nSrkftR8IxJ5Wec-1697717482-0-gaNycGzNDTs
https://coderwall.com/p/4tufta/herpes-zoster-market-trends-and-developments-in-2023
https://midi.org/forum/20192-herpes-zoster-market-future-prospects-in-2023
https://tapas.io/ybhardwaj
https://photozou.jp/user/top/3328982
https://b.hatena.ne.jp/entry?url=https%3A%2F%2Fwww.delveinsight.com%2Freport-store%2Fherpes-zoster-market
https://www.thingiverse.com/dennydones9/designs
https://soundcloud.com/dennydones
https://experiment.com/users/dennydones9
https://lichess.org/@/dennydones9
https://www.nicovideo.jp/user/130955053
https://menwiki.men/wiki/Main_Page
https://historydb.date/wiki/2_Bonus_Paling_Penting_di_Agen_Sbobet88_Terpercaya
https://mozillabd.science/wiki/Main_Page
https://championsleage.review/wiki/Main_Page
https://timeoftheworld.date/wiki/Main_Page
https://funsilo.date/wiki/Main_Page
https://opensourcebridge.science/wiki/Main_Page
https://scientific-programs.science/wiki/Main_Page
https://lovewiki.faith/wiki/Main_Page
https://influence.co/dennydones9999
https://www.awwwards.com/dennydones9999/
https://www.producthunt.com/discussions/pharma-competitive-intelligence-tracking-services-navigating-the-pharmaceutical-landscape
https://forum.ngs.ru/profile/3132957/
https://zrzutka.pl/profile/delveinsight-295941
https://sound-social.com/story5059347/healthcare-competitive-intelligence-tracking-services
https://socialmarkz.com/story5419072/healthcare-competitive-intelligence-tracking-services
https://network-373.mn.co/posts/41603294
https://www.hogwartsishere.com/1562170/
https://www.renderosity.com/users/id:1400373
https://hitrecord.org/users/dennydones9999/records
https://3dwarehouse.sketchup.com/user/0e9f9584-794e-4467-ac59-79db9efbadd9/Denny-Dones
https://www.atlasobscura.com/users/dennydones1
https://freedomlifestyle.mn.co/posts/41604435
https://socialmediainuk.com/story15310402/healthcare-competitive-intelligence-tracking-services
https://onlinedhan.mn.co/posts/41604571
https://skeleton-girls.mn.co/posts/41716585
https://network-89593.mn.co/posts/41716670
https://shaman-leaders.mn.co/posts/41716806
https://walkinvirtualclinics.mn.co/posts/41716883
https://machineintelligence.mn.co/posts/the-role-of-healthcare-partner-identification-services
https://vjudge.net/user/dennydones9999
https://yizhanverse.mn.co/posts/41717293
https://demo.plushforums.com/profile/18/denny-dones
https://www.sideprojectors.com/user/profile/69119
https://bookmarkstumble.com/story16655285/healthcare-partner-identification-services
https://bookmarkstime.com/story15535182/healthcare-partner-identification-services
http://baigasciedil.vforums.co.uk/profile/dennydones9999
http://weareone.vforums.co.uk/profile/dennydones9999
http://astarsuzuki.vforums.co.uk/profile/dennydones9999
http://proweb.vforums.co.uk/action/view_profile/user/dennydones9999
http://taresources.vforums.co.uk/action/view_profile/user/dennydones9999
http://gothicskin.vforums.co.uk/profile/dennydones9999
http://graphics.vforums.co.uk/profile/dennydones9999
http://clapecasna.vforums.co.uk/profile/dennydones9999
http://freuniontest.vforums.co.uk/profile/dennydones9999
http://whatwentwrong.vforums.co.uk/profile/dennydones9999
http://dog199200test.vforums.co.uk/profile/dennydones999911
http://system.vforums.co.uk/profile/dennydones9999
http://upsclan.vforums.co.uk/profile/dennydones999911
http://hairetevi.vforums.co.uk/profile/dennydones9999
http://dog199200test.vforums.co.uk/profile/dennydones999911
http://vfscomp2.vforums.co.uk/profile/dennydones9999
http://gamersgetaway.vforums.co.uk/profile/dennydones9999
http://surreyjobs.vforums.co.uk/profile/dennydones9999
http://support2.vforums.co.uk/profile/dennydones9999
http://swlsupport.vforums.co.uk/profile/dennydones9999
http://slipalimer.vforums.co.uk/profile/dennydones990099
http://art.vforums.co.uk/profile/dennydones990099
http://styles.vforums.co.uk/profile/dennydones990099
http://ghofertech.vforums.co.uk/profile/dennydones990099
http://dcdesign.vforums.co.uk/profile/dennydones990099
http://musicspot.vforums.co.uk/profile/dennydones990099
http://prov.vforums.co.uk/profile/dennydones990099
http://russell.vforums.co.uk/profile/dennydones990099
http://makethemes.vforums.co.uk/profile/dennydones990099
http://famousads.vforums.co.uk/profile/dennydones990099
http://pinkness.vforums.co.uk/profile/dennydones990011
http://elseandrew.vforums.co.uk/profile/dennydones99
http://suigacartsing.vforums.co.uk/profile/dennydones99
http://calanaera.vforums.co.uk/profile/dennydones99
http://legstudios.vforums.co.uk/action/view_profile/user/dennydones99
http://idirectory-old.vforums.co.uk/profile/dennydones99
http://skegness.vforums.co.uk/profile/dennydones99
http://futurexistence.vforums.co.uk/action/view_profile/user/dennydones99
http://codes.vforums.co.uk/profile/dennydones99
http://isgicaflo.vforums.co.uk/profile/dennydones99
http://profewovxi.vforums.co.uk/profile/dennydones99
http://zacsplace.vforums.co.uk/profile/dennydones99
http://sneeznavilas.vforums.co.uk/profile/dennydones99
http://coderspalace.vforums.co.uk/profile/dennydones991199
http://guide.vforums.co.uk/profile/dennydones99
http://deviantrhapsody.vforums.co.uk/profile/dennydones99
http://deviantrhapsody.vforums.co.uk/profile/dennydones99
http://rs2devolution.vforums.co.uk/action/view_profile/user/dennydones99
http://englishporcelain.vforums.co.uk/profile/dennydones99
https://scratchgram-2nd-instagram2.mn.co/posts/navigating-the-healthcare-landscape-with-competitive-intelligence-tracking-services
https://network-84066.mn.co/posts/42686849
https://www.canadavideocompanies.ca/author/dennydones1/
https://monvelli.mn.co/posts/42687788
https://fishjines.mn.co/posts/42688039
https://diecast64.mn.co/posts/42688112
https://mighty-men.mn.co/posts/42688183
https://team-clo.mn.co/posts/unveiling-the-power-of-healthcare-competitive-intelligence-tracking-services
https://stackoverflow.com/users/22614429/denny-dones?tab=profile
https://waarnemingen.be/users/791405/
https://keywebco.mn.co/posts/healthcare-competitive-intelligence-tracking-services-unveiling-the-future-of-healthcare-strategy

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking

This release was published on openPR.